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Abstract
Anti-Müllerianhormone (AMH) is an essentialmessengerof sexual differentiation in the foetus and is an emergingbiomarkerof
postnatal reproductive function in females. Due to a paucity of adequately sized studies, the genetic determinants of circulating
AMH levels are poorly characterized. In samples from 2815 adolescents aged 15 from the ALSPAC study, we performed the first
genome-wide association study of serum AMH levels across a set of ∼9  ‘1000 Genomes Reference Panel’ imputed genetic
variants. Genetic variants at the AMH protein-coding gene showed considerable allelic heterogeneity, with both common
variants [rs4807216 (PMale = 2 × 10
−49, Beta: ∼0.9 SDs per allele), rs8112524 (PMale = 3 × 10−8, Beta: ∼0.25)] and low-frequency
variants [rs2385821 (PMale = 6 × 10
−31, Beta: ∼1.2, frequency 3.6%)] independently associated with apparently large effect sizes in
males, but not females. For all three SNPs, we highlight mechanistic links to AMH gene function and demonstrate highly
significant sex interactions (PHet 0.0003–6.3 × 10
−12), culminating in contrasting estimates of trait variance explained (24.5% in
males versus 0.8% in females). Using these SNPs as a genetic proxy for AMH levels, we found no evidence in additional datasets
to support a biological role for AMH in complex traits and diseases in men.
Introduction
The gonadal hormone anti-Müllerianhormone (AMH) is an essen-
tial messenger of sexual differentiation. In the male foetus, AMH
results in involution of the Müllerian ducts, allowing Wolffian
ducts to develop into the male reproductive tract under the influ-
ence of testosterone. In the female foetus, the absence of AMH
allows the Müllerian duct to differentiate into uterine-fallopian
internal reproductive structures. Pathological disruption of AMH
activity in XY karyotype males leads to the persistent Müllerian
duct syndrome, a rare condition in which atypical development
of the uterus and sometimes other Müllerian structures occurs
(1,2). Raremutations underlying this autosomal recessive disorder
have been mapped to the AMH protein-encoding gene (AMH) and
its receptor (AMHR2); however, ∼15% of cases are idiopathic (3).
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In recent years, the development of sensitive assays for AMH
has allowed many studies of the role of postnatal AMH levels
(which are ∼10-fold lower than in the foetus) as a gonadalmarker
in both sexes. In pre-pubertal boys, measurement of serum
AMH is performed in clinical settings as a reliable indicator of
functional testes; its absence supports the diagnosis of primary
hypogonadism (4–5). In women, serum AMH has emerged
as the most robust circulating biomarker of reproductive
lifespan (6). Produced by ovarian granulosa cells, AMH levels
are highly correlated with ovarian primordial follicle number
and levels gradually decline with age until becoming undetect-
able ∼5 years before menopause when the follicle stock is
depleted (7–10).
In epidemiological studies, the association of serum AMH le-
vels with a broad range of cardio-metabolic traits in women has
been assessed, with conflicting results suggesting higher levels
are associated with increased disease risk (11,12), reduced risk
(13,14) and null associations (15–18). However, in all cases the
causal nature of these relationships is unknown, not least be-
cause the associations have been cross-sectional, predominantly
in small numbers and selected groups with polycystic ovary syn-
drome, sub-fertility or assessed during pregnancy. Genetic stud-
ies have the potential to aid these epidemiological analyses as
associationswith genetic variants are not subject to confounding
or reverse causality (19). Where available, such genetic variants
have been analysed as proxy instruments tomake valuable infer-
ences regarding the likely causal associations. However, few
large studies have measured AMH levels and GWAS data, and
there are as yet no common genetic variants identified with ro-
bust associations with serum AMH levels that could be used as
instrumental variables to assess causal associations.
Here, we report the first genome-wide association study
(GWAS) of serum AMH levels in a sample of 1360 males and
1455 females from the ALSPAC birth cohort study. We identified
several genetic variants at the AMH locus, which explain a sub-
stantial proportion of the population variance in AMH levels in
males, but not in females. Following on from this, we completed
a phenome scan in both ALSPAC males and deCODE (males and
females combined) studies to generate hypotheses around po-
tential causal effects of AMH on a range of phenotypes, which
found no evidence for a causal role in over 2500 human
disease/traits tested.
Results
A GWAS for serum AMH levels in adolescents
Natural log-transformed serum AMH levels were higher in 1360
males compared with 1455 females from the ALSPAC study (Sup-
plementary Material, Table S1). The GWAS for logged AMH levels
in all 2815 adolescents (females and males combined) identified
a total of 113 variants associated with serum AMH levels beyond
the genome-wide significance threshold, all of which were lo-
cated in/near the AMH protein-coding gene (Table 1 and Fig. 1).
The lead SNP was located 430 bp downstream of AMH [mean dif-
ference in AMH = ∼0.34 standard deviations (SD) per allele,
P = 1.8 × 10−18].
Independent signals at the AMH gene locus
Given the large number of variants associated at this locus with a
broad range of allele frequencies (MAF 2–40%), we tested for the
presence of multiple statistically independent signals at the
AMH locus. An analysis conditioning on the effect of the lead
SNP (rs4807216) revealed an additional low-frequency SNP
(rs2385821) at genome-wide significance (Table 1). This second
SNP was in moderate LD (r2 = 0.22) with the lead index SNP, but
its addition to a joint model increased the variance explained
in serumAMH from2.7%by rs4807216 alone to 5.2% by both SNPs.
AMH-associated variants exhibit sex-specific effects
We next aimed to identify variants with sex-specific effects on
AMH by performing two stratified analyses in the subsets of 1360
males and 1455 females. No variants reached genome-wide
significance in females; however, a strong signal, represented by
the same lead SNP as in the combined analysis, was observed in
males (Table 1; rs4807216, P = 7 × 10−50). A test for heterogeneity
revealed a striking sex interaction for this lead SNP [PHet = 9.3 ×
10−22], which was not associated with AMH levels in females
(P = 0.67).
We repeated conditional analyses in the sex-specific strata
and found three independent signals at the AMH gene locus in
males (Table 1), only one of which showed any evidence of even
potential association with AMH levels in females (rs2385821,
P = 8 × 10−4). In a joint model, all three SNPs demonstrated
Table 1. Genome-wide significant associations observed at the AMH gene locus
SNP Distancea Formatb Univariatec Joint modeld GCTA modele Variance (%)f
Betag P Beta P Beta P
All rs4807216 430 bp C/T/0.14 0.25 (0.03) 1.8E–18 0.33 (0.04) 3.E–20 0.34 (0.04) 2.4E–21 5.60
rs2385821 129 kb G/A/0.964 0.16 (0.05) 0.002 0.51 (0.06) 5.E–18 0.53 (0.06) 3.9E–18
rs8112524 Intronic G/A/0.39 0.16 (0.02) 6.7E–13 0.08 (0.03) 2.E–03 0.09 (0.03) 0.0004
Males rs4807216 430 bp C/T/0.14 0.46 (0.03) 7.4E–50 0.53 (0.04) 2.E–49 0.56 (0.04) 6.0E–45 24.50
rs2385821 129 kb G/A/0.964 0.14 (0.06) 0.02 0.7 (0.06) 6.E–31 0.78 (0.07) 1.9E–28
rs8112524 Intronic G/A/0.39 0.3 (0.02) 2.0E–34 0.15 (0.03) 3.E–08 0.18 (0.03) 1.3E–09
Females rs4807216 430 bp C/T/0.14 0.01 (0.04) 0.67 0.09 (0.05) 7.E–02 0.08 (0.04) 0.06 0.80
rs2385821 129 kb G/A/0.964 0.17 (0.06) 0.008 0.25 (0.07) 8.E–04 0.25 (0.07) 0.0009
rs8112524 Intronic G/A/0.39 0.01 (0.03) 0.81 0.002 (0.03) 9.E–01 −0.001 (0.03) 0.97
aDistance from AMH protein-coding gene.
bEffect allele/other allele/effect allele frequency.
cUnadjusted test statistics from the primary genome-wide association scan.
dEffect estimates when all three SNPs are jointly included in the regression model.
eEffect estimates when all three SNPs are jointly included in the GCTA approximate conditional analysis framework.
fTrait variance explained by all three SNPs.
gAll effect estimates based on natural log-transformed ng/ml serum AMH.
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significant heterogeneity between sexes (rs4807216 PHet = 6.3 ×
10−12, rs2385821 PHet = 1 × 10
−6 and rs8112524 PHet = 0.0003), with
widely contrasting estimates of the phenotypic variance ex-
plained in a model using all three SNPs: 24.5% in males versus
0.8% in females. To examine whether sex differences in AMH le-
vels and/or variability influenced the gene × sex interactions, we
examined a sub-sample of 713 boys and girls matched for an
identical AMH mean and SD. These demonstrated a very similar
pattern of sex-specific associations (results available from
authors on request).
We sought to confirm the identification of these statistically
independent signals using an ‘approximate conditional analysis’
methodology implemented in GCTA (20), run only on summary
level statistics. Highly concordant effect estimateswere observed
in a GCTA joint model (Table 1), further highlighting the utility of
this methodology.
Functional assessment of AMH-associated SNPs
To identify the potential mechanism(s) linking SNP association
to AMH function, we assessed publicly available gene expression
data from the GTex consortium (www.gtexportal.org), in addition
to searching for correlated non-synonymous variants. All three
SNPs were associated with AMH mRNA transcript levels in mul-
tiple tissue types (Supplementary Material, Table S3, Pmin 6 ×
10−5–1 × 10−15). The lead SNP for AMH protein levels (rs4807216)
was also the same lead SNP for the strongest genome-wide signal
for AMHmRNA levels (skeletalmuscle, P = 1 × 10−15); however, for
rs4807216 (and also rs8112524) the mRNA increasing allele was
associated with decreased protein levels, despite directionally
concordant effects on mRNA across all significant tissues. Two
of the three SNPswere correlated (r2 > 0.5) withmissense variants
in AMH (rs4807216 r2 = 0.54 with rs10407022; rs2385821 r2 = 0.55
with rs10417628).
Mendelian randomization phenome-wide scan
of AMH-associated variants
We performed a ‘Mendelian Randomisation’ analysis to test the
likely causal relevance of circulating AMH levels on a broad
range of human disease and health-related traits. Using our
newly identified SNPs as a genetic proxy for AMH, we found no
evidence for a causal relationship between AMH and complex se-
lected available traits in the ALSPAC males (trait N = 30, P > 0.002;
Supplementary Material, Table S2). Nor did we find any evidence
of association in deCODE (males and females combined; trait
N = 2528, P > 2 × 10−5; Supplementary Material, Figs. S1 and S2).
Discussion
Our study represents the first large-scale effort to elucidate the
genetic architecture of circulating AMH levels. As with other
sex hormones, progress in identifying genetic determinants has
been relatively slow comparedwith other complex traits, primar-
ily due to a paucity of data. Other studied sex hormones (and
their binding proteins) include testosterone (21,22), dehydroe-
piandrosterone sulphate (23) and sex hormone binding globulin
(SHBG) (24). In keeping with several of these studies, we demon-
strate a strong cis effect of variants at the protein-coding gene
locus, including evidence for multiple independent regulatory
elements. We also demonstrate sex-differentiated effects; how-
ever, we note that the dichotomy observed between sexes in
our study is stronger than any previously reported for a genetic
effect on a sex hormone. We hypothesize that the relative lack
of polygenicity in male AMH reflects its non-essential role in
adult health, with no strong selection acting on these alleles. A
total of three statistically independent signals were identified
through formal conditional analysis, with highly concordant re-
sults obtained through approximate conditional analysis. We
Figure 1. Regional association plot at the AMH gene region.
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found that two of the three identified signals were in high LD with
AMH missense alleles, one of which has been experimentally de-
monstrated to influence bioactivity of the AMH protein (25).
Each of these was also associated with AMH gene expression in
multiple tested tissues. Paradoxically the expression raising al-
lele decreased protein levels for two of these signals; however,
there are a number of likely explanations, such as effects on
RNA splicing leading to differential isoform expression and nu-
merous post-transcriptional and translational events affecting
processes such as protein secretion into the circulation. In aggre-
gate these data convincingly link our genetic variation to AMH
gene function; however, further fine-mapping studies and ex-
perimental evidence are required to elucidate the molecular
mechanism(s).
Aside from insight into the genetic regulation of AMH, the
identification of associated genetic variants has utility to inform
broader biomedical questions. The principles of ‘Mendelian Ran-
domization’ have been widely utilized to model genetic variants
as non-confounded proxies for traits of interest (26–31). Notable
examples in the context of reproductive biology include causal
effects of SHBG on T2D (32,33) and BMI on age at menarche
(34,35). Given the relatively large effect of AMH-related SNPs on
male AMH levels (explaining 25% of its variation), we can con-
clude that it is unlikely that circulatingAMH levels are a strong in-
fluencing factor for common traits and disease outcomes inmen.
Given the relatively weak genetic effect in females, we were
unable to assess what further role circulating levels may have
on the tested health outcomes in females. While the phenome
scan in deCODE is undertaken in females and males combined
(due to our access to these combined summary data only), the re-
sults should be interpreted as reflecting a Mendelian randomiza-
tion study in males only since the genetic instrument explains
very little variation in AMH in females. Currently AMH testing
is used in a number of diagnostic settings, including for ovarian
reserve measurement where it remains a leading predictive bio-
marker test (36,37). Biomarkers that are good predictors of an out-
come are not necessarily causally related. Future studies
identifying and assessing the effect of genetic variation on
AMH levels may look to integrate such genetic data into these
diagnostic tests to improve predictive power. This approach has
been demonstrated for PSA levels, where genetic correction for
the biomarker improved prostate cancer diagnosis (38). The rela-
tively small effect of our identified variants on female AMH levels
likely excludes this as a possibility until a time when additional
genetic determinants have been identified.
We note a number of limitations of this study. First, due to a
paucity of available data, we were unable to replicate our identi-
fied genetic signals. However, the highly relevant nature of the
gene locus and our closely supporting functional evidence pro-
vide confidence that these are real signals for AMH levels. Exag-
geration of the true effect sizes due to ‘winners curse’ may be
present, and it will be important for future studies to better esti-
mate the true effect in both sexes. However, even if the true effect
estimate was half the size observed here, the genetic variants
would still explain >10% of AMH variability in males. Second, al-
though two separate statistical approaches revealed evidence for
at least three independent effects, it remains possible that a
smaller number of untyped causal variants could explain this
apparent allelic heterogeneity (39). This can ultimately only
be resolved through fine-mapping approaches; however, the
relatively high degree of coverage provided by the 1000 genomes
reference panel reduces this possibility. Third, AMH was deter-
mined when participants were largely postpubertal, and al-
though in males this is likely to reflect adult levels, in females
AMH continues to increase until approximately age 25 years
(40). Replication of our findings in older cohorts is warranted
to exclude any age-specific genotype effects. Finally, the
hypothesis-free phenome scan in deCODE was restricted to a
sex-combined analysis using only the lead AMHSNP. This limita-
tion, alongwith the conservative Bonferroni correction threshold
applied to the tested diseases/traits, reduces our power to iden-
tify possible subtle effects of AMH on health-related outcomes
and, as noted earlier, we would interpret these null results as
being generalizable to males only.
In summary, these genome-wide analyses have identified the
first genetic variants robustly associated with serum AMH levels.
Given their relatively large effects, we were able to use these
variants as genetic instruments to infer that variability in AMH
levels is unlikely to substantially contribute to complex traits
and disease susceptibility in males.
Methods
The Avon Longitudinal Study of Parents and Children (ALSPAC) is
a longitudinal, population-based birth cohort that recruited
14 541 pregnant women resident in Avon, UK, with expected
dates of delivery 1 April 1991 to 31 December 1992 (http://www.
alspac.bris.ac.uk.) (41,42). Since age 7, surviving offspring partici-
pants have been invited to regular follow-up clinics. A total of
5515 adolescents attended the 14–16 (mean age 15 years) clinic,
of which 5376 were singletons; only singletons are considered
here. Detailed summary statistics of the AMH phenotyped
study population have been described elsewhere (18,43).
Ethical approval was obtained from the ALSPAC Law and
Ethics Committee (IRB 00003312) and the Local Research Ethics
Committee. The study website contains details of all the data
that is available through a fully searchable data dictionary (http://
www.bristol.ac.uk/alspac/).
Genotyping
Within ALSPAC, the index child participants, studied here, were
genotyped using the Illumina HumanHap550 quad genome-
wide SNP genotyping platform by Sample Logistics and Genotyp-
ing Facilities at theWellcome Trust Sanger Institute and LabCorp
(Laboratory Corportation of America) using support from
23andMe. Participants were excluded on the basis of having in-
correct sex assignments; minimal or excessive heterozygosity
(<0.32 and >0.345 for the Sanger data and <0.31 and >0.33 for
the LabCorp data); disproportionate levels of individual SNP
missingness (>3%); evidence of cryptic relatedness (>10% IBD)
and being of non-European ancestry. EIGENSTRAT analysis
revealed no additional obvious population stratification, and
genome-wide analyseswith other phenotypes indicate little gen-
omic inflation of association estimates in this population. The re-
sulting dataset consisted of 8365 individuals. SNPs with a minor
allele frequency of <1% and call rate of <95% were removed. Fur-
thermore, only SNPs that passed Exact tests of Hardy–Weinberg
equilibrium (P > 5 × 10−7) were considered for analysis. We com-
bined 477 482 SNPs genotypes of these subjects with genotype
data of a sample of 9048mothers to allow the use of a large num-
ber of duos by the phasing algorithm to increase quality of
phased haplotypes and downstream imputation. This resulted
in the removal SNPs genotypes with a poor concordance across
datasets, which could be completely captured by increasing the
missingness filter 5–1% (an additional 11 396 SNPs). We also re-
moved a further 321 subjects due to potential id mismatches
when assessed using duo data. We estimated haplotypes using
ShapeIT (v2.r644), which utilizes relatedness during phasing.
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We imputedwith Impute2 v2.2.2 using the 1000 genomes phase 1
version 3 reference data panel. This gave 8237 eligible adoles-
cents with available genotype data after exclusion of related sub-
jects using cryptic relatedness measures described previously.
AMH measurement
Participants were asked to fast overnight, for those attending in
the morning, or for a minimum of 6 h, for those attending in
the afternoon. Following venepuncture, blood samples were im-
mediately spun, plasma separated, and frozen at−80°C. AMHwas
assayed in heparin plasma, after a median 10 months storage
with no freeze-thaw cycles, using the commercial AMH Gener-
ation II ELISA kit (Beckman Coulter UK Ltd, High Wycombe, UK)
(43,44). Inter and intra-assay CVs were both <5%.
Association testing
SerumAMH levels were natural log-transformed prior to analysis
with outliers ±4 SDs removed, approximating a normal distribu-
tion (Supplementary Material, Table S1). Association testing was
performed using a linear regression model implemented in
SNPTest v2.5. The analysis was run three times—in males only,
in females only and in all individuals with sex as a covariate. Sig-
nificance was declared at the genome-wide threshold of P < 5 ×
10−8. Independent genetic signals were identified using two ap-
proaches—approximate conditional analysis implemented in
GCTA using UK10K genotypes as a reference panel; and formal
conditional analyses were performed by re-running the GWAS
with the inclusion of the tested SNP(s) as covariates.
Mendelian randomization
Using our newly identified genetic variants as a proxy instrument
for circulating AMH levels, we performedMendelian Randomiza-
tion analyses using two complementary approaches. First, male
specific analyses were performed across 30 biologically plausible
outcomes in theALSPAC study (SupplementaryMaterial, Table S1).
The number of copies of the reference allele of each of the three
AMH-relatedSNPs identifiedafterassociation testingwereweigh-
ted by their adjusted effect size and direction of effect in PLINK
(v1.07). SNP rs4807216 reference allele C was weighted by 0.533,
SNP rs2385821 reference allele G was weighted by 0.699 and
SNP rs8112524 reference allele G was weighted by 0.145. Each in-
dividual was thereby scored as a weighted sum of the number of
reference alleles for these three SNPs, and the resulting values
were used as an independent variable in a linear regression of
health-related outcomes.
Second, we utilized a hypothesis-free approach by testing the
association of the most strongly associated AMH SNP with 2528
traits or diseases in a sex-combined cohort from the deCODE
study (45), with a maximum trait sample size of 104 220. A con-
servative significance threshold was declared at a Bonferroni
level of P < 0.05/N traits tested.
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